Galapagos N.V. (0JXZ)
London Exchange · UK · prices in EUR · close of 21 Oct 2026
Key indicators
| Last close | EUR 27.32 |
|---|---|
| 52-week range | 22.38 – 30.52 |
| Return, 1 month / 3 months | +3.4% / +11.1% |
| Return, 1 year / 3 years | −1.1% / −14.8% |
| Trend | Uptrend |
| RSI (14) | 62 |
| Volatility (1 year) | 28.7% |
| Worst drawdown (1 year) | -25.2% |
| Average daily value traded | 0.05M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Galapagos is a biopharmaceutical company based in Belgium that discovers and develops medicines for inflammatory diseases and other serious conditions. It has worked on small-molecule treatments, including a medicine for rheumatoid arthritis and ulcerative colitis developed with a partner, and it is building a pipeline in cell therapy and oncology. Its customers are mainly healthcare providers and patients through partners and its own commercial operations in Europe.
Galapagos N.V. trades under the code 0JXZ on the London Exchange in UK, with its price quoted in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Galapagos N.V. (0JXZ) trades on the London Exchange in UK. It last closed at EUR 27.32 on 21 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 1,785 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 1.1% and over the last three months it rose 11.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 57 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 5.5% | ||
| From 52-week high | -9.3% | ||
| Momentum | 61 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 11.1% | ||
| 6-month return | 10.6% | ||
| 12-month return, skipping the last month | -4.4% | ||
| Stability (higher is calmer) | 62 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 28.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.2% | ||
| Liquidity | 24 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.05M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +5.9% |
|---|---|
| 1 month | +3.4% |
| 3 months | +11.1% |
| 6 months | +10.6% |
| 1 year | −1.1% |
| 3 years | −14.8% |
| 5 years | −38.0% |
Signals
| 50-day / 200-day average | 25.36 / 25.90 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.63 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.